veterinari
vaccin
current
avail
europ
part
world
develop
veterinari
pharmaceut
industri
develop
vaccin
veterinari
use
econom
endeavour
take
mani
year
mani
obstacl
along
path
success
develop
launch
vaccin
industri
develop
vaccin
veterinari
use
usual
start
proof
concept
base
robust
academ
research
vaccin
made
avail
veterinari
commun
market
authoris
grant
veterinari
author
review
give
brief
descript
regulatori
requir
fulfil
vaccin
admit
market
vaccin
produc
qualiti
control
environ
guarante
deliveri
product
consist
qualiti
well
defin
anim
consum
safeti
efficaci
characterist
regulatori
manufactur
legisl
framework
develop
take
place
describ
well
trend
develop
product
system
recent
develop
bacteri
viral
parasit
vaccin
research
develop
also
address
develop
novel
adjuv
use
expand
knowledg
immunolog
diseas
patholog
describ
industri
develop
veterinari
vaccin
start
proof
concept
establish
proof
concept
base
robust
academ
explor
fundament
scienc
scientif
literatur
report
mani
academ
proof
variou
novel
vaccin
concept
recent
year
industri
vaccin
develop
program
see
tabl
phase
start
proof
concept
demonstr
eventu
lead
market
authoris
ie
permiss
place
vaccin
market
grant
appropri
veterinari
author
contrast
academ
proof
concept
demonstr
industri
develop
vaccin
seen
econom
context
veterinari
vaccin
produc
market
pharmaceut
compani
competit
one
anoth
veterinari
vaccin
two
main
target
market
recognis
dynam
market
agricultur
product
anim
sector
companion
anim
recent
decad
gener
trend
agricultur
sector
becom
industri
price
sensit
contrast
public
percept
companion
anim
chang
lead
increas
demand
medicin
care
gener
vaccin
product
anim
produc
larger
quantiti
low
cost
wherea
vaccin
companion
anim
produc
lower
quantiti
sold
higher
price
moreov
realis
difficult
profitmak
enterpris
justifi
develop
vaccin
diseas
low
incid
vaccin
speci
kept
low
number
schetter
apart
oper
cost
expens
compli
legal
regulatori
requir
manufactur
regulatori
requir
continu
review
vaccin
could
regist
year
ago
may
registr
today
owe
chang
regulatori
framework
furthermor
regulatori
requir
sometim
difficult
fulfil
particular
vaccin
concept
vaccin
produc
industri
scale
govern
certifi
manufactur
facil
good
manufactur
practic
gmp
requir
incorpor
law
describ
detail
manufactur
standard
sinc
introduct
veterinari
medicin
product
licens
europ
year
ago
econom
environ
increas
legal
regulatori
pressur
chang
agricultur
sceneri
lead
mark
consolid
among
veterinari
vaccin
manufactur
review
first
outlin
regulatori
manufactur
legal
context
eu
second
discuss
develop
product
method
third
describ
concept
viral
bacteri
parasit
vaccin
immun
potenti
vaccin
anim
like
medicin
product
licens
relev
author
ensur
medicin
adequ
qualiti
puriti
safe
work
target
speci
claim
indic
intend
jone
et
al
schetter
gravendyck
licens
veterinari
vaccin
formal
introduc
eu
cd
cd
eec
cd
cd
eudralex
ph
eur
inform
test
result
requir
guidelin
cd
cd
cd
cd
ph
eur
demonstr
qualiti
puriti
safeti
efficaci
compil
dossier
base
dossier
review
question
gather
requir
inform
test
result
vaccin
vaccin
develop
usual
organis
structur
well
phase
manner
variou
develop
phase
distinguish
summaris
tabl
flow
chart
key
stage
develop
given
fig
regul
may
cours
chang
cours
develop
may
impact
develop
time
cost
market
vaccin
manufactur
licens
gmp
certif
facil
involv
manufactur
vaccin
requir
addit
licens
describ
briefli
qualiti
safeti
efficaci
gmp
manufactur
requir
veterinari
vaccin
soulebot
et
al
ensur
consist
qualiti
product
method
technolog
underli
vaccin
must
oper
complianc
principl
current
gmp
monitor
qualiti
assur
system
cd
eudralex
vaccin
product
gmp
requir
law
cd
eudralex
qualiti
start
materi
use
product
assur
test
batch
purchas
made
ensur
meet
accept
limit
addit
requir
exist
start
materi
biolog
origin
commonli
use
vaccin
product
eg
ensur
exclus
extran
agent
seed
stock
vaccin
strain
product
celllin
laid
seed
lot
system
make
passag
master
seed
establish
bank
work
seed
product
batch
produc
initi
master
seed
must
known
histori
isol
previou
passag
minimis
risk
transmiss
transmiss
spongiform
encephalopathi
tse
addit
puriti
absenc
extran
agent
bacteria
fungi
mycoplasma
virus
ident
vaccin
antigen
need
demonstr
ensur
batch
commerci
vaccin
equival
qualiti
manufactur
must
regist
relev
process
test
well
test
perform
finish
product
give
limit
accept
must
met
batch
releas
sale
addit
manufactur
must
prove
qualiti
vaccin
produc
semi
commerci
scale
guarante
end
shelf
life
base
least
three
batch
vaccin
final
contain
safeti
paramount
import
determin
safeti
fundament
firm
purpos
benefit
product
outweigh
potenti
risk
target
speci
vaccin
also
administr
vaccin
environ
food
test
batch
product
small
scale
live
vaccin
low
passag
lot
safeti
glp
target
speci
includ
pregnant
anim
case
indic
requir
high
passag
lot
efficaci
onset
immun
durat
immun
inactiv
vaccin
high
passag
lot
safeti
glp
efficaci
licens
batch
commerci
scale
gmp
consist
product
process
valid
transfer
product
process
control
test
manufactur
depart
qualiti
control
depart
stabil
studi
antigen
final
product
final
contain
field
studi
gcp
safeti
efficaci
deriv
treat
anim
food
deriv
consum
experiment
data
obtain
batch
highest
potenc
titr
see
must
gener
special
design
experi
carri
good
laboratori
practic
glp
regimen
cd
oecd
addit
safeti
singl
dose
safeti
overdos
repeat
dose
vaccin
must
shown
inject
site
reaction
clinic
sign
safeti
studi
design
accord
recommend
schedul
use
suscept
target
speci
addit
special
requir
live
vaccin
genet
stabil
ie
vaccin
revert
virul
consecut
passag
risk
genet
recombin
andor
genom
reassort
minim
also
studi
immunolog
function
reproduct
capac
may
carri
depend
natur
vaccin
adjuv
diseas
addit
requir
met
vaccin
contain
genet
modifi
organ
gmo
product
must
abl
claim
label
eg
reduc
viru
shed
limit
typic
clinic
sign
diseas
prefer
data
obtain
field
trial
perform
good
clinic
practiceveterinari
condit
laboratori
studi
possibl
valid
experiment
challeng
model
use
onset
durat
immun
instanc
day
onset
year
durat
follow
yearli
vaccin
sustain
level
immun
must
support
experiment
data
data
must
show
year
primari
vaccin
anim
still
satisfactorili
protect
also
anim
receiv
singl
booster
vaccin
year
initi
vaccin
still
protect
year
later
confirm
protect
effect
specif
antigen
usual
establish
vaccinationchalleng
experi
protect
effect
correl
altern
laboratori
anim
vitro
test
carri
batch
finish
vaccin
pass
level
batch
releas
set
minimum
level
shown
efficaci
target
anim
correl
protect
correl
protect
unknown
may
take
year
accur
potenc
test
develop
moreov
manufactur
must
provid
data
guarante
immunis
capabl
therebi
protect
effect
product
entir
shelf
life
eu
grant
approv
summari
product
characterist
spc
describ
pharmaceut
form
product
categori
target
anim
contraind
recommend
vaccin
schedul
rout
administr
moreov
spc
contain
recommend
use
withdraw
period
use
product
advic
minimis
risk
concurr
infect
vaccin
period
could
interfer
induct
activ
immun
respons
sinc
licens
veterinari
vaccin
formal
introduc
eu
requir
activ
ingredi
antigen
finish
product
vaccin
must
manufactur
accord
gmp
cd
cd
eudralex
apart
valid
method
test
prevent
mainten
system
inplac
critic
equip
build
respons
key
personnel
key
depart
document
polici
document
trend
analysi
differ
paramet
util
environment
monitor
process
control
ipc
provid
use
inform
process
perform
qualiti
gener
test
process
must
valid
report
includ
build
equip
moreov
everi
one
qualiti
relat
system
procedur
polici
written
site
master
file
even
commerci
product
necessari
make
chang
process
test
develop
full
oper
gmp
qualiti
system
still
possibl
optimis
process
make
signific
improv
chang
chang
control
system
ensur
chang
formal
request
document
approv
impact
chang
market
authoris
valid
statu
process
need
determin
document
detail
may
regulatori
consequ
moreov
vaccin
produc
must
employ
least
one
qualifi
person
without
prejudic
relationship
holder
manufactur
authoris
person
respons
releas
vaccin
onto
market
cd
cd
cd
regular
intern
extern
audit
compet
author
aim
survey
qualiti
control
procedur
inplac
describ
increas
regulatori
gmp
econom
burden
impos
vaccin
manufactur
necessit
develop
reliabl
largescal
antigen
product
method
use
cell
cultur
substrat
recent
year
quest
highli
product
cell
cultur
process
focus
frontend
continu
celllin
develop
rather
use
primari
cell
chicken
embryo
fibroblast
cef
improv
protein
express
system
high
throughput
screen
method
cell
characteris
techniqu
enabl
develop
product
stabl
celllin
use
antigen
product
final
product
qualiti
consum
safeti
alreadi
consid
celllin
develop
ie
earli
stage
vaccin
develop
project
develop
transit
animalcomponentfre
cultur
media
cell
identif
suitabl
animalfre
replac
certain
compon
bovin
serum
ultim
develop
fulli
chemic
defin
cultur
media
exampl
consider
increas
need
higher
antigen
yield
combin
shorter
product
develop
product
process
time
sophist
product
process
develop
method
requir
everi
stage
process
earli
develop
scaleup
larg
volum
current
gener
miniatur
bioreactor
work
volum
millilitr
model
largescal
cell
cultur
process
provid
capabl
examin
differ
condit
within
singl
experi
offer
opportun
understand
process
cellular
level
enabl
better
predict
extrapol
largescal
bioreactor
process
establish
analyt
technolog
enabl
inlin
monitor
antigen
product
advantag
studi
import
immunogen
antigen
properti
glycosyl
cell
metabolit
influenc
overal
growth
cell
consequ
antigen
contribut
consist
reliabl
scalabl
entir
process
earli
effort
produc
protein
express
bacteria
yeast
mammalian
cell
commerci
quantiti
requir
costli
reusabl
hardwar
involv
extens
clean
resterilis
process
valid
process
requir
rule
setout
gmp
regul
longstand
approach
place
heavi
demand
standard
oper
procedur
sop
usual
result
high
cost
extens
personnel
train
signific
cost
involv
manufactur
facil
time
repres
total
manufactur
cost
plant
valid
account
plant
cost
cost
reduc
increas
facil
throughput
term
number
campaign
run
per
year
increas
antigen
yield
per
run
instal
equip
allow
plant
oper
multipurpos
multiproduct
product
facil
option
adopt
biotech
manufactur
effort
reduc
cost
move
dispos
manufactur
use
throw
away
technolog
use
mani
manufactur
variou
stage
product
process
result
improv
throughput
reduc
amount
downtim
campaign
also
allow
develop
multipurpos
plant
design
flexibl
use
dispos
system
exist
clean
room
furthermor
dispos
individu
compon
whole
system
elimin
long
lead
time
initi
manufactur
instal
stainless
steel
equip
design
dispos
system
primarili
dictat
applic
usual
custom
made
key
factor
take
consider
design
phase
applic
may
volum
process
chemic
compat
product
number
product
run
per
year
process
condit
pressur
temperatur
flow
rate
mix
time
sensit
product
extract
materi
present
plastic
valid
support
vendor
current
wide
use
compon
includ
contain
filtrat
connect
clamp
bioreactor
tube
nowaday
mani
compound
biotechnolog
product
suit
suppli
hard
pipe
stainless
steel
dispos
system
compon
alreadi
suppli
preassembl
sterilis
signific
reduct
made
contamin
risk
valid
effort
labour
time
preassembl
dispos
compon
dramat
increas
manufactur
depend
suppli
may
jeopardis
sustain
deliveri
vaccin
product
tabl
alreadi
indic
dispos
system
contain
extract
compon
dispos
materi
leak
product
stream
may
interfer
antigen
product
product
safeti
manufactur
dispos
system
undertak
extract
test
use
model
solvent
part
valid
protocol
howev
system
user
must
gener
valid
data
demonstr
extract
advers
affect
product
store
process
within
dispos
done
worstcas
exposur
condit
base
known
characterist
product
model
solvent
cover
entir
dispos
assembl
moreov
plastic
definit
anim
componentfre
dispos
also
compli
tse
guidelin
tabl
use
dispos
technolog
still
requir
hardwar
control
panel
need
initi
valid
mainten
element
current
manufactur
process
centrifug
largescal
chromatographi
largescal
tangenti
flow
filtrat
system
yet
avail
dispos
option
inlin
real
time
monitor
product
process
still
develop
stage
dispos
sensor
technolog
also
yet
avail
mean
clean
inplac
discard
expens
reusabl
sensor
avoid
sensor
togeth
make
process
uncontrol
tabl
recent
improv
chromatographi
tff
equip
asept
fluid
transfer
devic
well
improv
plastic
film
strength
resist
lead
eventu
replac
tradit
stainless
steel
gmp
manufactur
compon
singleus
dispos
format
think
even
ahead
develop
total
dispos
manufactur
system
imagin
dispos
factori
may
becom
commonplac
depend
larg
new
dispos
product
develop
evolut
regulatori
gmp
guidelin
industri
adapt
develop
shown
introduct
shortterm
dispos
mix
monitor
system
bacteri
vaccin
mainli
inactiv
whole
cell
cultur
bacterin
inactiv
cultur
supernat
toxoid
crude
extract
cell
surfac
attenu
live
prepar
advanc
knowledg
biolog
technolog
give
opportun
develop
improv
vaccin
inactiv
crude
prepar
advantag
knowledg
molecular
basi
pathogenesi
prerequisit
vaccin
develop
sinc
good
chanc
contain
antigen
necessari
stimul
protect
immun
disadvantag
greater
potenti
antigen
competit
andor
divers
immun
respons
protect
antigen
nonetheless
present
prepar
fail
usual
contain
lipopolysaccharid
techoic
acid
cell
wall
constitu
compon
led
heavi
stimul
innat
immun
system
undesir
advers
effect
like
nonetheless
tradit
approach
remain
perfectli
accept
accept
solut
certain
diseas
andrefontain
et
al
earli
live
vaccin
advantag
inactiv
antigen
combin
potenti
vivo
depend
gene
express
provid
protect
immun
stimulu
feberwe
et
al
nonspecif
unstabl
genet
alter
inher
vaccin
could
lead
suboptim
growth
adequ
immun
stimulu
ie
attenu
insuffici
attenu
prevent
advers
reaction
revers
virul
ie
attenu
revers
fashion
later
vaccin
develop
took
advantag
new
studi
molecular
basi
bacteri
pathogenesi
initi
depend
physicochem
separ
bacteri
compon
assess
interact
isol
host
tissu
cell
biochemistri
addit
effect
immunis
purifi
prepar
outcom
experiment
challeng
epidemiolog
distribut
efficaci
compon
amongst
clinic
nonclin
isol
moon
bunn
taken
account
studi
herald
introduct
first
socal
subunit
vaccin
later
still
introduct
molecular
clone
enabl
genet
isol
characteris
protect
immunogen
particular
construct
hostvector
combin
enhanc
express
recombin
antigen
provid
higher
yield
less
reactiv
vaccin
compon
cheapli
petersen
et
al
commerci
avail
vaccin
develop
method
first
introduc
compar
recent
time
arriv
whole
bacteri
genom
sequenc
bioinformat
analys
predict
structur
function
cellular
locat
sequenc
develop
microarray
analysi
whole
genom
express
bring
revolut
design
develop
bacteri
vaccin
particularli
case
diseas
tradit
approach
efficaci
scarselli
et
al
simpl
term
gene
hypothet
identifi
bacteri
pathogen
possibl
construct
array
site
solid
sheet
contain
bound
synthet
dna
complementari
gene
genom
messeng
rna
mrna
extract
bacteria
live
differ
environ
use
prepar
probe
strength
proportion
amount
mrna
speci
present
time
extract
detect
differ
strength
probe
hybridis
gene
array
possibl
see
gene
level
express
chang
rel
differ
environ
gene
upregul
vivo
cultur
design
mimic
vivo
environ
bioinformat
analys
indic
like
surfac
express
secret
critic
stage
host
colonis
pathogenesi
henc
access
interfer
host
immun
enabl
identif
attract
candid
vaccin
antigen
without
necessarili
know
function
possibl
delet
gene
question
confirm
role
pathogenesi
challeng
model
also
produc
recombin
purifi
antigen
use
vaccin
trial
provid
antigen
reason
conserv
amongst
clinic
isol
strategi
provid
power
rout
efficaci
vaccin
develop
crude
prepar
past
achiev
desir
level
efficaci
safeti
technolog
make
possibl
creat
live
vaccin
incap
revers
virul
minim
interfer
express
import
protect
immunogen
whilst
inactiv
power
immun
divert
immunogen
may
interfer
strength
efficaci
respons
dna
vaccin
rel
recent
consider
gene
encod
protect
immunogen
insert
nonrepl
element
abl
taken
host
cell
initi
express
foreign
antigen
intracellularli
present
cell
surfac
associ
mhc
antigen
cell
offer
advantag
balanc
immun
respons
modul
achiev
effect
immun
dna
highli
stabl
room
temperatur
easili
qualiti
assur
qa
control
product
jechling
unfortun
mani
project
payload
dna
requir
prohibit
expens
new
technolog
need
along
line
adjuv
enhanc
respons
antigen
one
ironi
molecular
genom
approach
protect
subunit
antigen
dna
vaccin
often
poor
immunogen
associ
bacteri
compon
present
crude
prepar
nonspecif
enhanc
immun
respons
say
inher
adjuv
properti
consequ
new
adjuv
strategi
need
make
recombin
subunit
dna
vaccin
work
bacteria
may
provid
solut
intens
investig
adjuv
cholera
escherichia
coli
heat
labil
adpribosyl
enterotoxin
lyck
zonula
occluden
toxin
vibrio
cholera
de
magistri
mycobacterium
tuberculosi
heat
shock
protein
bulut
et
al
salmonella
typhimurium
fljb
simon
samuel
synthet
analog
bacteri
lipoprotein
ghielmetti
et
al
synthet
oligodeoxynucleotid
contain
unmethyl
cpg
dinucleotid
mccluski
krieg
gomi
et
al
monophosphoryl
lipid
jiang
et
al
veterinari
bacteri
vaccin
develop
still
call
upon
perfectli
valid
tradit
techniqu
start
era
bacteri
behaviour
gene
genom
allow
us
predict
need
success
control
diseas
matter
time
efficaci
vaccin
could
realiti
almost
bacteri
diseas
market
virus
belong
subfamili
caus
signific
diseas
hors
pig
cattl
poultri
genom
sever
member
herpesviru
subfamili
sequenc
molecular
virolog
play
signific
role
identif
virulenceassoci
viru
encod
gene
function
wittmann
rziha
mettenleit
kimman
et
al
led
develop
effect
safe
convent
well
biotechnolog
marker
vaccin
kit
et
al
marchioli
et
al
quint
et
al
pensaert
et
al
van
oirschot
delet
mutant
biotech
approach
particularli
success
pseudorabi
viru
prv
bovin
herpesviru
contrast
equin
delet
nonessenti
viru
glycoprotein
enzym
gene
aim
deriv
attenu
live
viru
vaccin
candid
similar
prv
fruitless
patel
helden
howev
clear
need
improv
vaccin
particularli
protect
induc
abort
paresi
also
reduc
incid
therefor
transmiss
unwean
passiv
immun
foal
patel
helden
regard
highli
promis
experiment
vaccin
temperaturesensit
ts
strain
clone
classic
mutagenis
stock
abortigen
isol
patel
et
al
b
patel
et
al
marek
diseas
viru
mdv
occur
worldwid
caus
signific
loss
chicken
mdv
develop
vector
newcastl
diseas
viru
glycoprotein
recombin
vaccin
effect
commerci
marek
diseas
viru
vaccin
poultri
contain
cellassoci
low
passag
variant
origin
rispen
isol
quest
gener
efficaci
safe
cellfre
mdv
vaccin
use
convent
biotech
approach
unsuccess
far
despit
veterinari
medicin
logist
need
vaccin
porcin
caus
multiorgan
diseas
signific
econom
loss
domest
pig
allan
elli
krakowa
et
al
immunoprophylaxi
infect
domest
pig
convent
biotech
vaccin
baculoviru
express
protein
addit
mani
biotech
experiment
vaccin
investig
exampl
vaccin
orf
gene
express
prv
vector
apathogen
chimera
vaccin
dna
plasmid
vaccin
fenaux
et
al
kamstrup
et
al
chunmei
et
al
routin
prophylact
vaccin
classic
swine
fever
viru
csfv
eu
ceas
westergaard
outsid
eu
convent
vaccin
well
biotech
glycoprotein
subunit
marker
vaccin
wide
use
lin
lee
van
oirschot
de
smit
et
al
sever
biotech
approach
investig
csfv
vaccin
includ
baculoviru
express
glycoprotein
ahren
et
al
chimer
bovin
viru
diarrhoea
viru
bvdv
csfv
vaccin
van
gennip
et
al
recombin
prv
express
glycoprotein
protect
diseas
due
prv
csfv
van
zijl
et
al
biotech
vaccin
experiment
allow
serolog
discrimin
vaccin
infect
anim
allow
use
csfv
vaccin
previous
ban
applic
biotech
approach
protect
bvdv
vaccin
includ
glycoprotein
express
product
baculoviru
defect
bvdv
replicon
biotech
bvdv
vaccin
current
avail
eu
choic
live
kill
convent
vaccin
straub
howev
three
kill
vaccin
claim
afford
protect
bvdv
abort
brownli
et
al
patel
et
al
salt
et
al
last
decad
west
nile
viru
wnv
caus
signific
diseas
hors
anim
speci
includ
man
becom
potent
threat
current
biotech
vaccin
market
use
hors
canarypox
viru
vector
live
vaccin
chimer
wnv
glycoprotein
yellow
fever
viru
backbon
vaccin
monath
influenza
virus
caus
greater
problem
bird
mammal
particular
strain
subtyp
highli
pathogen
caus
high
mortal
pose
zoonot
risk
man
along
subtyp
eu
vaccin
avian
influenza
discourag
emphasi
chang
capua
alexand
like
approach
develop
vaccin
would
first
clone
site
direct
mutagenesi
turn
hagen
nonpathogen
form
second
product
socal
high
growth
reassort
produc
consider
amount
new
ha
protein
among
other
protect
antigen
influenza
viru
latter
achiev
revers
genet
transfect
techniqu
wood
robertson
approach
current
circul
potenti
pandem
avian
influenza
viru
caus
human
death
far
biotech
approach
clone
chang
hagen
viral
vector
newcastl
diseas
viru
ndv
carri
well
revers
genet
use
alter
cleavag
site
ndvf
protein
far
convent
live
kill
vaccin
domin
market
nonrepl
vector
avipoxviru
approach
canarypox
viru
express
canin
distemp
viru
hf
glycoprotein
gene
market
usa
sinc
modern
biotech
vaccin
approach
alway
give
better
vaccin
howev
avian
influenza
instanc
shown
field
classic
grown
inactiv
vaccin
formul
potent
adjuv
offer
crossprotect
relat
pathogen
strain
swayn
et
al
african
swine
fever
asf
highli
contagi
fatal
diseas
pig
caus
iridoviru
asfv
effect
vaccin
clearli
need
indic
possibl
mettraux
et
al
commerci
develop
approach
howev
never
undertaken
econom
reason
unsuccess
reason
manufactur
difficulti
african
hors
sick
ah
highli
fatal
insect
transmit
diseas
equida
caus
african
hors
sick
viru
ahsv
orbiviru
current
convent
mous
brain
tissu
cultur
grown
vaccin
use
futur
vaccin
may
use
ahsv
protein
subunit
biotech
vaccin
ranz
et
al
case
asfv
commerci
develop
approach
never
undertaken
econom
reason
unsuccess
owe
manufactur
difficulti
bluetongu
viru
btv
whilst
eggadapt
polyval
vaccin
preval
serotyp
use
biotech
approach
investig
hold
much
promis
thu
btvlike
viru
corelik
structur
construct
use
major
minor
capsid
protein
vp
protein
produc
baculoviru
multipl
express
vector
viruslik
singl
doubl
shell
particl
emulsifi
freund
incomplet
adjuv
montanid
adjuv
highli
immunogen
protect
sheep
roy
approach
hold
promis
sinc
baculoviru
express
vector
differ
btv
serotyp
could
prepar
advanc
store
bank
similar
line
foot
mouth
diseas
viru
fmdv
westergaard
brought
outbreak
occur
convent
rabi
viru
vaccin
mostli
kill
immunis
variou
mammalian
speci
common
use
rabi
viru
one
exampl
biotech
approach
like
make
good
progress
latter
well
exemplifi
attempt
reduc
incid
wildlif
rabi
mostli
red
fox
vulp
vulp
mainland
europ
replic
recombin
vaccinia
viru
express
rabi
viru
glycoprotein
highli
effect
reduc
incid
wildlif
rabi
mainland
europ
pastoret
brochier
westergaard
monoval
subunit
felin
leukaemia
viru
felv
glycoprotein
express
e
coli
market
eu
immunogen
experiment
vaccinia
viru
recombin
express
bovin
leukaemia
viru
envelop
protein
given
promis
result
bovin
calv
rabbit
valikhov
et
al
import
relev
point
anim
diseas
vaccin
present
diseas
affect
domest
wild
rumin
deer
instanc
wildlif
diseas
current
unknown
undetect
may
transmit
domest
anim
possibl
man
recent
notabl
exampl
anim
virus
cross
man
retrovirus
like
hiv
sar
coronaviru
west
nile
viru
avian
influenza
subtyp
viru
gamma
herpesvirus
name
alcephalin
herp
ovin
caus
fatal
excess
lymphoid
prolifer
secondari
deadend
secondari
rumin
host
name
cattl
deer
speci
nettleton
et
al
reid
buxton
plowright
hussey
et
al
innocu
reservoir
host
wildebeest
sheep
respect
two
retrovirus
one
belong
subfamili
lentiviru
visnamaedi
viru
caprin
arthritisenceph
viru
one
subfamili
oncoviru
sheep
pulmonari
adenomatosi
viru
caus
signific
diseas
sheep
vaccin
avail
similarli
possibl
present
control
veterinari
retrovirus
bovin
leukaemia
avian
type
c
oncoviru
reticuloendotheliosi
viru
two
new
fatal
zoonot
infect
due
relat
paramyxovirus
name
hendra
nipah
virus
affect
hors
pig
respect
also
man
reservoir
virus
petropid
bat
found
australia
far
east
haplin
et
al
current
vaccin
avail
virus
classic
import
parasit
diseas
human
anim
treat
andor
control
use
chemotherapeut
cornelissen
schetter
seri
develop
includ
drug
resist
given
impetu
research
parasit
vaccin
result
number
vaccin
parasit
diseas
commerci
avail
envis
parasit
vaccin
come
market
aid
control
parasit
diseas
vercruyss
et
al
mani
parasit
diseas
host
develop
level
immun
infect
cure
indic
parasit
suffici
immunogen
potenti
could
exploit
vaccin
research
aim
develop
vaccin
andor
vaccin
protocol
induc
protect
immun
limit
induct
patholog
differ
approach
recogn
vari
use
live
vaccin
attenu
live
vaccin
kill
vaccin
subunit
vaccin
obviou
exampl
vaccin
live
vaccin
coccidiosi
chicken
william
type
infect
transient
parasit
pass
chicken
infect
selflimit
chemotherapeut
treatment
necessari
cure
infect
limit
induct
patholog
necessari
defin
lowdos
given
anim
infect
initi
simultan
chicken
flock
virul
parasit
strain
deriv
singl
isol
variabl
exampl
use
babesia
bovi
isol
passag
splenectomis
anim
select
strain
reduc
virul
parasit
strain
use
vaccin
cattl
africa
australia
infect
develop
less
virul
anim
develop
immun
subsequ
challeng
infect
de
waal
combrink
vaccin
distribut
govern
institut
similarli
strain
reduc
virul
select
eimeria
isol
commerci
avail
coccidiosi
vaccin
broiler
contain
strain
select
repeat
passag
chicken
socal
precoci
strain
requir
less
time
develop
oocyst
number
progeni
reduc
compar
wildtyp
parent
popul
william
parasit
strain
select
differ
wildtyp
strain
caus
selflimit
infect
one
exampl
temperaturesensit
strain
toxoplasma
gondii
strain
result
chemic
induc
attenu
propag
success
vitro
rel
low
temperatur
propag
success
bodi
temperatur
target
anim
result
infect
selfcur
lindsay
et
al
vaccin
commercialis
case
parasit
tendenc
surviv
host
longer
period
time
chemotherapeut
cure
infect
also
requir
exampl
approach
live
vaccin
theileria
parva
infect
vaccin
base
isol
virul
parva
strain
use
infect
cattl
simultan
treat
longact
tetracyclin
prepar
control
infect
boulter
hall
method
still
use
africa
vaccin
produc
centr
tick
tick
born
diseas
cttbd
malawi
mani
parasit
speci
complic
lifecycl
characteris
distinct
lifecycl
stage
sometim
involv
one
host
case
earli
lifecycl
stage
suffici
immunogen
induc
protect
immun
select
parasit
strain
truncat
lifecycl
anoth
strategi
develop
vaccin
good
exampl
gondii
strain
strain
lost
capac
develop
tachyzoit
bradyzoit
stage
thu
form
tissu
cyst
tachyzoit
induc
transient
infect
host
trigger
protect
immun
reaction
buxton
irradi
parasit
also
use
mechan
truncat
lifecycl
live
vaccin
lungworm
infect
cattl
contain
larva
dictyocaulu
viviparu
develop
stage
vaccin
cattl
immun
challeng
larva
urquhart
theoret
virul
parasit
strain
could
genet
modifi
reduc
virul
instanc
parasit
strain
could
genet
manipul
product
vaccin
parasit
would
fulli
virul
administ
host
would
caus
selflimit
infect
principl
investig
use
toxoplasma
gondii
tetracyclinedepend
regulatori
element
clone
front
essenti
gene
parasit
may
propag
vaccin
product
phase
presenc
tetracyclin
inject
target
anim
parasit
abl
continu
propag
absenc
tetracyclin
lead
block
express
essenti
gene
van
poppel
et
al
live
vaccin
strain
avail
use
live
vaccin
undesir
one
may
want
inactiv
parasit
prior
formul
vaccin
prepar
induc
protect
immun
appropri
adjuv
formul
must
develop
exampl
vaccin
vaccin
abort
cattl
due
neospora
caninum
infect
schetter
vaccin
giardiasi
dog
olson
et
al
detail
analysi
immun
respons
acquir
natur
infect
vaccin
induc
immun
lead
discoveri
critic
antigen
compon
organ
use
vaccin
prepar
requir
adjuv
induct
protect
immun
vaccin
babesiosi
dog
due
babesia
cani
infect
one
exampl
schetter
contain
solubl
antigen
secret
excret
parasit
research
shown
b
cani
infect
dog
antigen
releas
caus
diseas
vaccin
help
anim
quickli
produc
neutralis
antibodi
antigen
adjuv
appear
critic
saponin
work
wherea
oilbas
adjuv
shown
littl
efficaci
schetter
case
antigen
produc
use
recombin
dna
technolog
best
exampl
vaccin
taenia
ovi
sheep
base
recombinantli
produc
parasit
antigen
induc
antibodi
block
attach
oncospher
gut
epithelium
harrison
et
al
saponin
adjuv
shown
efficaci
anoth
exampl
vaccin
cattl
tick
boophilu
microplu
willadsen
vaccin
contain
recombinantli
produc
gut
wall
antigen
tick
upon
vaccin
cattl
high
level
antibodi
gut
wall
tick
produc
feed
tick
vaccin
anim
antibodi
ingest
destroy
gut
epithelium
tick
thu
kill
parasit
recent
time
immunopotenti
receiv
abund
attent
media
critic
adjuv
novel
human
vaccin
exampl
includ
prophylact
vaccin
human
papilloma
viru
hpv
novel
pandem
influenza
viru
well
experiment
allergi
tumour
vaccin
inde
vaccin
adjuv
also
refer
major
platform
technolog
recognis
make
differ
compet
vaccin
base
ident
antigen
addit
recognis
vaccin
design
certain
diseas
requir
match
combin
select
antigen
togeth
critic
immunopotenti
select
drive
essenti
immun
pathway
minim
advers
reaction
increas
awar
immunopotenti
import
promin
particular
among
human
vaccinologist
veterinari
vaccin
design
applic
import
adjuv
alway
evid
tradit
veterinari
vaccin
consist
rel
crude
extract
microbi
cultur
inher
immunogen
rel
purifi
subunit
peptid
antigen
prefer
human
vaccin
obvious
constitut
antigen
interest
may
contribut
immunogen
overal
level
immun
respons
anoth
trend
recent
year
increas
zscientif
knowledg
mechanist
activ
mani
immunopotenti
especi
result
research
focus
innat
immun
receptor
insight
enabl
ration
adjuv
vaccin
design
ideal
base
predict
immunophenotyp
follow
vaccin
schijn
et
al
schijn
et
al
highlight
recent
develop
immunopotenti
mechanist
vaccin
adjuv
classifi
two
major
group
vaccin
deliveri
system
facilit
time
dose
geographi
antigen
also
call
facilit
signal
signal
facilit
directli
activ
certain
innat
immun
cell
degen
et
al
vaccin
adjuv
also
influenc
qualiti
immun
respons
sinc
may
prefer
instruct
develop
helper
th
regulatori
cell
reg
stimulu
origin
refer
signal
kapsenberg
et
al
immunopotenti
make
vaccin
work
evok
potenti
antigenspecif
b
cell
respons
poorli
immunogen
subunit
vaccin
crude
antigen
prepar
respect
larg
determin
immunophenotyp
respons
antigen
vaccin
exampl
vaccin
adjuv
abl
influenc
acceler
onset
immun
may
becom
urgent
emerg
vaccin
earli
age
posthatch
birth
offspr
microbi
attack
vaccin
adjuv
may
also
increas
overal
magnitud
antigenspecif
respons
order
reach
minim
level
protect
antibodi
concentr
effector
cell
popul
addit
adjuv
prolong
durat
vaccin
effector
immun
respons
allow
fewer
booster
immunis
becom
critic
mass
vaccin
moreov
certain
vaccin
adjuv
abl
posit
affect
qualiti
immunophenotyp
exampl
induct
cellmedi
cell
immun
consid
necessari
control
mani
type
intracellular
pathogen
antigen
dose
cost
spare
enabl
certain
adjuv
relev
case
expens
cumbersom
antigen
product
system
importantli
immunopotenti
may
caus
transient
unwant
advers
reaction
either
inject
site
system
level
accept
depend
rel
benefit
vaccin
medic
need
prevent
treat
diseas
interest
unfortun
singl
adjuv
need
instead
mani
differ
choic
potenti
immunopotenti
ration
select
vaccin
adjuv
vaccin
design
hamper
limit
knowledg
immunophenotyp
evok
classic
vaccin
adjuv
select
best
immunopotenti
long
matter
trialanderror
serendip
fortun
recent
time
mechanist
studi
base
new
insight
especi
innat
immun
receptor
allow
systemat
scientif
investig
immun
induct
gener
immunopotenti
particular
hold
mice
human
best
studi
immun
system
increasingli
speci
veterinari
relev
new
knowledg
allow
develop
new
improv
immunopotentiatorbas
prophylact
vaccin
well
novel
therapeut
vaccin
vaccin
play
import
role
control
anim
diseas
particularli
food
produc
industri
howev
current
larg
achiev
convent
develop
produc
vaccin
progress
veterinari
vaccin
develop
industri
larg
influenc
boundari
set
regulatori
gmp
econom
constraint
outlin
obviou
reason
regulatori
requir
strict
strengthen
ensur
deliveri
safe
efficaci
vaccin
gmp
glp
qualiti
system
develop
achiev
end
proof
concept
new
vaccin
qa
system
implement
stage
vaccin
develop
earli
phase
seed
materi
produc
gmp
regimen
wherea
final
stage
fulli
oper
gmp
system
appli
burden
place
vaccin
manufactur
caus
develop
reliabl
flexibl
largescal
product
method
develop
cell
cultur
system
animalcomponentfre
cultur
media
multipurpos
facil
dispos
manufactur
materi
clear
exampl
trend
background
dealt
current
trend
industri
name
use
biotechnolog
vaccin
develop
product
exampl
success
biotech
classic
vaccin
approach
given
bacteri
viral
parasit
vaccin
respect
viru
diseas
separ
review
deal
detail
epidemiolog
pathogenesi
vaccin
avail
develop
written
patel
helden
accept
public
give
complet
comprehens
overview
vaccin
option
develop
market
indic
number
biotechnologybas
vaccin
present
market
late
stage
develop
bacteri
viral
parasit
pathogen
rather
limit
expect
product
base
biotechnologybioengin
increas
futur
knowledg
work
mechan
adjuv
increas
base
progress
understand
anim
diseas
immunolog
adjuv
work
mechan
allow
ration
vaccin
design
notwithstand
fact
major
current
veterinari
vaccin
deriv
produc
convent
attenu
andor
inactiv
process
tissu
cultur
genet
engin
techniqu
wide
use
use
even
futur
yet
fulfil
promis
improv
vaccin
import
realis
perfect
vaccin
may
never
sinc
pathogen
constantli
mutat
order
surviv
evad
host
defenc
basic
academ
research
increas
understand
pathogen
behaviour
must
ongo
activ
improv
abil
protect
health
welfar
human
anim
accomplish
must
continu
improv
vaccin
made
industri
manner
